Literature DB >> 8478620

Prevention of autoimmune diabetes in non-obese diabetic mice by treatment with a class II major histocompatibility complex-blocking peptide.

U Hurtenbach1, E Lier, L Adorini, Z A Nagy.   

Abstract

The role of antigen presentation as a possible mechanism underlying major histocompatibility complex (MHC) association of autoimmune disease has been studied in non-obese diabetic (NOD) mice. By screening for inhibition of antigen presentation to NOD T cell hybridoma, we have selected a synthetic peptide, yTYTVHAAHAYTYt (small letters denote D amino acids), that efficiently blocks antigen presentation by the NOD class II MHC molecule A alpha g7A beta g7 (Ag7) in vitro. The inhibition is MHC selective, in that it does not affect antigen presentation by the E(d) and E(k) molecules, and has only a marginal effect on presentation by the A(d) molecule. This peptide also inhibits the priming for Ag7-restricted T cell responses in vivo, and prevents the spontaneous development of diabetes in female NOD mice, when administered chronically from 3 wk of age on. Chronic treatment with a control peptide, KMKMVHAAHAKMKM, that fails to bind to Ag7 has no effect on the disease. These data indicate that antigen presentation by the Ag7 molecule plays a pivotal role in the induction of autoimmune diabetes. Furthermore, the results demonstrate that interference with antigen presentation by a class II molecule can prevent the onset of spontaneous autoimmune disease associated with the same molecule.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8478620      PMCID: PMC2191014          DOI: 10.1084/jem.177.5.1499

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  30 in total

1.  The pharmacological properties of a new, orally active antianaphylactic compound: ketotifen, a benzocycloheptathiophene.

Authors:  U Martin; D Römer
Journal:  Arzneimittelforschung       Date:  1978

2.  Antigenic competition at the level of peptide-Ia binding.

Authors:  B P Babbitt; G Matsueda; E Haber; E R Unanue; P M Allen
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

3.  The first external domain of the nonobese diabetic mouse class II I-A beta chain is unique.

Authors:  H Acha-Orbea; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

Review 4.  HLA and disease 1982--a survey.

Authors:  A Svejgaard; P Platz; L P Ryder
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

5.  The NOD mouse: recessive diabetogenic gene in the major histocompatibility complex.

Authors:  M Hattori; J B Buse; R A Jackson; L Glimcher; M E Dorf; M Minami; S Makino; K Moriwaki; H Kuzuya; H Imura
Journal:  Science       Date:  1986-02-14       Impact factor: 47.728

6.  Autoimmune murine thyroiditis relation to histocompatibility (H-2) type.

Authors:  A O Vladutiu; N R Rose
Journal:  Science       Date:  1971-12-10       Impact factor: 47.728

7.  Immunogenetic control of experimental type II collagen-induced arthritis. I. Susceptibility and resistance among inbred strains of rats.

Authors:  M M Griffiths; E J Eichwald; J H Martin; C B Smith; C W DeWitt
Journal:  Arthritis Rheum       Date:  1981-06

8.  Effect of castration on the appearance of diabetes in NOD mouse.

Authors:  S Makino; K Kunimoto; Y Muraoka; K Katagiri
Journal:  Jikken Dobutsu       Date:  1981-04

9.  Regulation of the immune response to peptide antigens: differential induction of immediate-type hypersensitivity and T cell proliferation due to changes in either peptide structure or major histocompatibility complex haplotype.

Authors:  P Soloway; S Fish; H Passmore; M Gefter; R Coffee; T Manser
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

10.  Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates.

Authors:  P H Wooley; H S Luthra; J M Stuart; C S David
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

View more
  9 in total

Review 1.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

2.  Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease.

Authors:  Jiang Xia; Elin Bergseng; Burkhard Fleckenstein; Matthew Siegel; Chu-Young Kim; Chaitan Khosla; Ludvig M Sollid
Journal:  Bioorg Med Chem       Date:  2007-07-25       Impact factor: 3.641

Review 3.  Temporal discontinuities in progression of NOD autoimmune diabetes.

Authors:  G B Rudy; R M Sutherland; A M Lew
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

4.  Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes.

Authors:  G Rudy; N Stone; L C Harrison; P G Colman; P McNair; V Brusic; M B French; M C Honeyman; B Tait; A M Lew
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

5.  Determinant capture as a possible mechanism of protection afforded by major histocompatibility complex class II molecules in autoimmune disease.

Authors:  H Deng; R Apple; M Clare-Salzler; S Trembleau; D Mathis; L Adorini; E Sercarz
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

6.  Prevention of insulin-dependent diabetes mellitus in nonobese diabetic mice by immunogenic but not by tolerated peptides.

Authors:  M Vaysburd; C Lock; H McDevitt
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

7.  A peptide-binding motif for I-A(g7), the class II major histocompatibility complex (MHC) molecule of NOD and Biozzi AB/H mice.

Authors:  L C Harrison; M C Honeyman; S Trembleau; S Gregori; F Gallazzi; P Augstein; V Brusic; J Hammer; L Adorini
Journal:  J Exp Med       Date:  1997-03-17       Impact factor: 14.307

8.  CD4+ beta islet cell-reactive T cell clones that suppress autoimmune diabetes in nonobese diabetic mice.

Authors:  I Akhtar; J P Gold; L Y Pan; J L Ferrara; X D Yang; J I Kim; K N Tan
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

Review 9.  Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders.

Authors:  Masha Fridkis-Hareli
Journal:  Clin Dev Immunol       Date:  2013-11-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.